CIK 0001108205 · Non-accelerated filer<br>Smaller reporting company
CURIS INC
Sign in to watch- Ticker
- CRIS
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 043505116
- Phone
- 617-503-6500
- Business address
- 128 SPRING STREET, BUILDING C, SUITE 500, LEXINGTON, MA, 02421
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2013-05-02 | PASSERI DANIEL R CEO and Director | Sale | −50,000 | $3.66 | $183K | 150,750 |
| 2013-05-02 | PASSERI DANIEL R CEO and Director | Option exercise · Non-qualified stock option | −50,000 | 348,785 | ||
| 2013-05-02 | PASSERI DANIEL R CEO and Director | Option exercise | +50,000 | $2.43 | $122K | 200,750 |
| 2013-05-02 | PASSERI DANIEL R CEO and Director | Sale | −50,000 | $3.66 | $183K | 150,750 |
| 2013-05-02 | PASSERI DANIEL R CEO and Director | Option exercise · Non-qualified stock option | −50,000 | $2.43 | $122K | 0 |
| 2013-05-02 | GREENACRE MARTYN D Director | Option exercise | +60,000 | $1.09 | $65K | 95,138 |
| 2013-05-02 | GREENACRE MARTYN D Director | Sale | −60,000 | $3.67 | $220K | 35,138 |
| 2013-05-02 | GREENACRE MARTYN D Director | Option exercise · Non-qualified stock option (right to buy) | −60,000 | $2.43 | $146K | 0 |
| 2013-05-02 | NOEL MARK VP, Tech Management | Option exercise | +52,258 | $2.43 | $127K | 79,798 |
| 2013-05-02 | NOEL MARK VP, Tech Management | Sale | −52,258 | $3.66 | $191K | 27,540 |
| 2013-05-02 | NOEL MARK VP, Tech Management | Option exercise | +17,742 | $2.43 | $43K | 45,282 |
| 2013-05-02 | NOEL MARK VP, Tech Management | Sale | −17,742 | $3.66 | $65K | 27,540 |
| 2013-05-02 | NOEL MARK VP, Tech Management | Option exercise · Qualified stock option (right to buy) | +52,258 | $2.43 | $127K | 0 |
| 2013-05-02 | NOEL MARK VP, Tech Management | Option exercise · Nonqualified stock option (right to buy) | +17,742 | $2.43 | $43K | 0 |
| 2013-03-28 | Pienta Kenneth Director | Grant or award · Non-qualified stock option (right to buy) | +25,000 | 25,000 | ||
| 2013-02-19 | Fattaey Ali Ph.D. President & COO | Grant or award · Qualified stock option (right to buy) | +124,336 | $3.02 | $375K | 124,336 |
| 2013-02-19 | Fattaey Ali Ph.D. President & COO | Grant or award · Nonqualified stock option (right to buy) | +275,664 | $3.02 | $833K | 400,000 |
| 2013-01-17 | Martell Robert Director | Grant or award · Non-qualified stock option (right to buy) | +25,000 | 25,000 | ||
| 2013-01-17 | MCNAB JAMES R Director | Grant or award · Non-qualified stock option (right to buy) | +85,000 | 85,000 | ||
| 2013-01-17 | TOBIN JAMES R Director | Grant or award · Non-qualified stock option (right to buy) | +25,000 | 25,000 |
Page 16 of 17 · 326 trades